Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults
Background Accumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA treatment has been shown to improve glucose tolerance and to increase energy expenditure in mice. Here, we investigated the relationship between fasting plasma BAs concentrations and metabo...
Saved in:
| Published in | Nutrition & metabolism Vol. 8; no. 1; pp. 48 - 344 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
07.07.2011
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1743-7075 1743-7075 |
| DOI | 10.1186/1743-7075-8-48 |
Cover
| Abstract | Background
Accumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA treatment has been shown to improve glucose tolerance and to increase energy expenditure in mice. Here, we investigated the relationship between fasting plasma BAs concentrations and metabolic parameters in humans.
Findings
Fasting plasma glucose, insulin and lipid profile were measured in 14 healthy volunteers, 20 patients with type 2 diabetes (T2D), and 22 non-diabetic abdominally obese subjects. Insulin sensitivity was also assessed by the determination of the glucose infusion rate (GIR) during a hyperinsulinemic-euglycemic clamp in a subgroup of patients (9 healthy and 16 T2D subjects). Energy expenditure was measured by indirect calorimetry. Plasma cholic acid (CA), chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA) concentrations were analyzed by gas chromatograph-mass spectrometry. In univariable analysis, a positive association was found between HOMA-IR and plasma CDCA (β = 0.09, p = 0.001), CA (β = 0.03, p = 0.09) and DCA concentrations (β = 0.07, p < 0.0001). Spearman analysis retrieved an inverse relationship between plasma CDCA (r = -0.44, p = 0.03), CA (r = -0.65, p = 0.001) and the GIR. HOMA-IR remained positively associated with CDCA (β = 0.11, p = 0.01), CA (β = 0.04, p = 0.01) and DCA (β = 0.06, p = 0.007) in multivariable analysis, after adjustment for age, gender, BMI, HbA1C and plasma lipid parameters. In contrast, HbA1c, energy expenditure and plasma lipid concentrations were not correlated with plasma BAs levels in multivariable analysis.
Conclusions
Both plasma CDCA, CA and DCA concentrations were negatively associated with insulin sensitivity in a wide range of subjects. |
|---|---|
| AbstractList | Accumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA treatment has been shown to improve glucose tolerance and to increase energy expenditure in mice. Here, we investigated the relationship between fasting plasma BAs concentrations and metabolic parameters in humans.BACKGROUNDAccumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA treatment has been shown to improve glucose tolerance and to increase energy expenditure in mice. Here, we investigated the relationship between fasting plasma BAs concentrations and metabolic parameters in humans.Fasting plasma glucose, insulin and lipid profile were measured in 14 healthy volunteers, 20 patients with type 2 diabetes (T2D), and 22 non-diabetic abdominally obese subjects. Insulin sensitivity was also assessed by the determination of the glucose infusion rate (GIR) during a hyperinsulinemic-euglycemic clamp in a subgroup of patients (9 healthy and 16 T2D subjects). Energy expenditure was measured by indirect calorimetry. Plasma cholic acid (CA), chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA) concentrations were analyzed by gas chromatograph-mass spectrometry. In univariable analysis, a positive association was found between HOMA-IR and plasma CDCA (β = 0.09, p = 0.001), CA (β = 0.03, p = 0.09) and DCA concentrations (β = 0.07, p < 0.0001). Spearman analysis retrieved an inverse relationship between plasma CDCA (r = -0.44, p = 0.03), CA (r = -0.65, p = 0.001) and the GIR. HOMA-IR remained positively associated with CDCA (β = 0.11, p = 0.01), CA (β = 0.04, p = 0.01) and DCA (β = 0.06, p = 0.007) in multivariable analysis, after adjustment for age, gender, BMI, HbA1C and plasma lipid parameters. In contrast, HbA1c, energy expenditure and plasma lipid concentrations were not correlated with plasma BAs levels in multivariable analysis.FINDINGSFasting plasma glucose, insulin and lipid profile were measured in 14 healthy volunteers, 20 patients with type 2 diabetes (T2D), and 22 non-diabetic abdominally obese subjects. Insulin sensitivity was also assessed by the determination of the glucose infusion rate (GIR) during a hyperinsulinemic-euglycemic clamp in a subgroup of patients (9 healthy and 16 T2D subjects). Energy expenditure was measured by indirect calorimetry. Plasma cholic acid (CA), chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA) concentrations were analyzed by gas chromatograph-mass spectrometry. In univariable analysis, a positive association was found between HOMA-IR and plasma CDCA (β = 0.09, p = 0.001), CA (β = 0.03, p = 0.09) and DCA concentrations (β = 0.07, p < 0.0001). Spearman analysis retrieved an inverse relationship between plasma CDCA (r = -0.44, p = 0.03), CA (r = -0.65, p = 0.001) and the GIR. HOMA-IR remained positively associated with CDCA (β = 0.11, p = 0.01), CA (β = 0.04, p = 0.01) and DCA (β = 0.06, p = 0.007) in multivariable analysis, after adjustment for age, gender, BMI, HbA1C and plasma lipid parameters. In contrast, HbA1c, energy expenditure and plasma lipid concentrations were not correlated with plasma BAs levels in multivariable analysis.Both plasma CDCA, CA and DCA concentrations were negatively associated with insulin sensitivity in a wide range of subjects.CONCLUSIONSBoth plasma CDCA, CA and DCA concentrations were negatively associated with insulin sensitivity in a wide range of subjects. BACKGROUND: Accumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA treatment has been shown to improve glucose tolerance and to increase energy expenditure in mice. Here, we investigated the relationship between fasting plasma BAs concentrations and metabolic parameters in humans. FINDINGS: Fasting plasma glucose, insulin and lipid profile were measured in 14 healthy volunteers, 20 patients with type 2 diabetes (T2D), and 22 non-diabetic abdominally obese subjects. Insulin sensitivity was also assessed by the determination of the glucose infusion rate (GIR) during a hyperinsulinemic-euglycemic clamp in a subgroup of patients (9 healthy and 16 T2D subjects). Energy expenditure was measured by indirect calorimetry. Plasma cholic acid (CA), chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA) concentrations were analyzed by gas chromatograph-mass spectrometry. In univariable analysis, a positive association was found between HOMA-IR and plasma CDCA (beta=0.09, p=0.001), CA (beta=0.03, p=0.09) and DCA concentrations (beta=0.07, p<0.0001). Spearman analysis retrieved an inverse relationship between plasma CDCA (r=-0.44, p=0.03), CA (r=-0.65, p=0.001) and the GIR. HOMA-IR remained positively associated with CDCA (beta=0.11, p=0.01), CA (beta=0.04, p=0.01) and DCA (beta=0.06, p=0.007) in multivariable analysis, after adjustment for age, gender, BMI, HbA1C and plasma lipid parameters. In contrast, HbA1c, energy expenditure and plasma lipid concentrations were not correlated with plasma BAs levels in multivariable analysis. CONCLUSIONS: Both plasma CDCA, CA and DCA concentrations were negatively associated with insulin sensitivity in a wide range of subjects. BACKGROUND: Accumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA treatment has been shown to improve glucose tolerance and to increase energy expenditure in mice. Here, we investigated the relationship between fasting plasma BAs concentrations and metabolic parameters in humans. FINDINGS: Fasting plasma glucose, insulin and lipid profile were measured in 14 healthy volunteers, 20 patients with type 2 diabetes (T2D), and 22 non-diabetic abdominally obese subjects. Insulin sensitivity was also assessed by the determination of the glucose infusion rate (GIR) during a hyperinsulinemic-euglycemic clamp in a subgroup of patients (9 healthy and 16 T2D subjects). Energy expenditure was measured by indirect calorimetry. Plasma cholic acid (CA), chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA) concentrations were analyzed by gas chromatograph-mass spectrometry. In univariable analysis, a positive association was found between HOMA-IR and plasma CDCA (β = 0.09, p = 0.001), CA (β = 0.03, p = 0.09) and DCA concentrations (β = 0.07, p < 0.0001). Spearman analysis retrieved an inverse relationship between plasma CDCA (r = -0.44, p = 0.03), CA (r = -0.65, p = 0.001) and the GIR. HOMA-IR remained positively associated with CDCA (β = 0.11, p = 0.01), CA (β = 0.04, p = 0.01) and DCA (β = 0.06, p = 0.007) in multivariable analysis, after adjustment for age, gender, BMI, HbA1C and plasma lipid parameters. In contrast, HbA1c, energy expenditure and plasma lipid concentrations were not correlated with plasma BAs levels in multivariable analysis. CONCLUSIONS: Both plasma CDCA, CA and DCA concentrations were negatively associated with insulin sensitivity in a wide range of subjects. Background Accumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA treatment has been shown to improve glucose tolerance and to increase energy expenditure in mice. Here, we investigated the relationship between fasting plasma BAs concentrations and metabolic parameters in humans. Findings Fasting plasma glucose, insulin and lipid profile were measured in 14 healthy volunteers, 20 patients with type 2 diabetes (T2D), and 22 non-diabetic abdominally obese subjects. Insulin sensitivity was also assessed by the determination of the glucose infusion rate (GIR) during a hyperinsulinemic-euglycemic clamp in a subgroup of patients (9 healthy and 16 T2D subjects). Energy expenditure was measured by indirect calorimetry. Plasma cholic acid (CA), chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA) concentrations were analyzed by gas chromatograph-mass spectrometry. In univariable analysis, a positive association was found between HOMA-IR and plasma CDCA ([beta] = 0.09, p = 0.001), CA ([beta] = 0.03, p = 0.09) and DCA concentrations ([beta] = 0.07, p [less than] 0.0001). Spearman analysis retrieved an inverse relationship between plasma CDCA (r = -0.44, p = 0.03), CA (r = -0.65, p = 0.001) and the GIR. HOMA-IR remained positively associated with CDCA ([beta] = 0.11, p = 0.01), CA ([beta] = 0.04, p = 0.01) and DCA ([beta] = 0.06, p = 0.007) in multivariable analysis, after adjustment for age, gender, BMI, HbA1C and plasma lipid parameters. In contrast, HbA1c, energy expenditure and plasma lipid concentrations were not correlated with plasma BAs levels in multivariable analysis. Conclusions Both plasma CDCA, CA and DCA concentrations were negatively associated with insulin sensitivity in a wide range of subjects. Accumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA treatment has been shown to improve glucose tolerance and to increase energy expenditure in mice. Here, we investigated the relationship between fasting plasma BAs concentrations and metabolic parameters in humans. Fasting plasma glucose, insulin and lipid profile were measured in 14 healthy volunteers, 20 patients with type 2 diabetes (T2D), and 22 non-diabetic abdominally obese subjects. Insulin sensitivity was also assessed by the determination of the glucose infusion rate (GIR) during a hyperinsulinemic-euglycemic clamp in a subgroup of patients (9 healthy and 16 T2D subjects). Energy expenditure was measured by indirect calorimetry. Plasma cholic acid (CA), chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA) concentrations were analyzed by gas chromatograph-mass spectrometry. In univariable analysis, a positive association was found between HOMA-IR and plasma CDCA ([beta] = 0.09, p = 0.001), CA ([beta] = 0.03, p = 0.09) and DCA concentrations ([beta] = 0.07, p [less than] 0.0001). Spearman analysis retrieved an inverse relationship between plasma CDCA (r = -0.44, p = 0.03), CA (r = -0.65, p = 0.001) and the GIR. HOMA-IR remained positively associated with CDCA ([beta] = 0.11, p = 0.01), CA ([beta] = 0.04, p = 0.01) and DCA ([beta] = 0.06, p = 0.007) in multivariable analysis, after adjustment for age, gender, BMI, HbA1C and plasma lipid parameters. In contrast, HbA1c, energy expenditure and plasma lipid concentrations were not correlated with plasma BAs levels in multivariable analysis. Both plasma CDCA, CA and DCA concentrations were negatively associated with insulin sensitivity in a wide range of subjects. Accumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA treatment has been shown to improve glucose tolerance and to increase energy expenditure in mice. Here, we investigated the relationship between fasting plasma BAs concentrations and metabolic parameters in humans. Fasting plasma glucose, insulin and lipid profile were measured in 14 healthy volunteers, 20 patients with type 2 diabetes (T2D), and 22 non-diabetic abdominally obese subjects. Insulin sensitivity was also assessed by the determination of the glucose infusion rate (GIR) during a hyperinsulinemic-euglycemic clamp in a subgroup of patients (9 healthy and 16 T2D subjects). Energy expenditure was measured by indirect calorimetry. Plasma cholic acid (CA), chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA) concentrations were analyzed by gas chromatograph-mass spectrometry. In univariable analysis, a positive association was found between HOMA-IR and plasma CDCA (β = 0.09, p = 0.001), CA (β = 0.03, p = 0.09) and DCA concentrations (β = 0.07, p < 0.0001). Spearman analysis retrieved an inverse relationship between plasma CDCA (r = -0.44, p = 0.03), CA (r = -0.65, p = 0.001) and the GIR. HOMA-IR remained positively associated with CDCA (β = 0.11, p = 0.01), CA (β = 0.04, p = 0.01) and DCA (β = 0.06, p = 0.007) in multivariable analysis, after adjustment for age, gender, BMI, HbA1C and plasma lipid parameters. In contrast, HbA1c, energy expenditure and plasma lipid concentrations were not correlated with plasma BAs levels in multivariable analysis. Both plasma CDCA, CA and DCA concentrations were negatively associated with insulin sensitivity in a wide range of subjects. Abstract Background Accumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA treatment has been shown to improve glucose tolerance and to increase energy expenditure in mice. Here, we investigated the relationship between fasting plasma BAs concentrations and metabolic parameters in humans. Findings Fasting plasma glucose, insulin and lipid profile were measured in 14 healthy volunteers, 20 patients with type 2 diabetes (T2D), and 22 non-diabetic abdominally obese subjects. Insulin sensitivity was also assessed by the determination of the glucose infusion rate (GIR) during a hyperinsulinemic-euglycemic clamp in a subgroup of patients (9 healthy and 16 T2D subjects). Energy expenditure was measured by indirect calorimetry. Plasma cholic acid (CA), chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA) concentrations were analyzed by gas chromatograph-mass spectrometry. In univariable analysis, a positive association was found between HOMA-IR and plasma CDCA (β = 0.09, p = 0.001), CA (β = 0.03, p = 0.09) and DCA concentrations (β = 0.07, p < 0.0001). Spearman analysis retrieved an inverse relationship between plasma CDCA (r = -0.44, p = 0.03), CA (r = -0.65, p = 0.001) and the GIR. HOMA-IR remained positively associated with CDCA (β = 0.11, p = 0.01), CA (β = 0.04, p = 0.01) and DCA (β = 0.06, p = 0.007) in multivariable analysis, after adjustment for age, gender, BMI, HbA1C and plasma lipid parameters. In contrast, HbA1c, energy expenditure and plasma lipid concentrations were not correlated with plasma BAs levels in multivariable analysis. Conclusions Both plasma CDCA, CA and DCA concentrations were negatively associated with insulin sensitivity in a wide range of subjects. Background Accumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA treatment has been shown to improve glucose tolerance and to increase energy expenditure in mice. Here, we investigated the relationship between fasting plasma BAs concentrations and metabolic parameters in humans. Findings Fasting plasma glucose, insulin and lipid profile were measured in 14 healthy volunteers, 20 patients with type 2 diabetes (T2D), and 22 non-diabetic abdominally obese subjects. Insulin sensitivity was also assessed by the determination of the glucose infusion rate (GIR) during a hyperinsulinemic-euglycemic clamp in a subgroup of patients (9 healthy and 16 T2D subjects). Energy expenditure was measured by indirect calorimetry. Plasma cholic acid (CA), chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA) concentrations were analyzed by gas chromatograph-mass spectrometry. In univariable analysis, a positive association was found between HOMA-IR and plasma CDCA (β = 0.09, p = 0.001), CA (β = 0.03, p = 0.09) and DCA concentrations (β = 0.07, p < 0.0001). Spearman analysis retrieved an inverse relationship between plasma CDCA (r = -0.44, p = 0.03), CA (r = -0.65, p = 0.001) and the GIR. HOMA-IR remained positively associated with CDCA (β = 0.11, p = 0.01), CA (β = 0.04, p = 0.01) and DCA (β = 0.06, p = 0.007) in multivariable analysis, after adjustment for age, gender, BMI, HbA1C and plasma lipid parameters. In contrast, HbA1c, energy expenditure and plasma lipid concentrations were not correlated with plasma BAs levels in multivariable analysis. Conclusions Both plasma CDCA, CA and DCA concentrations were negatively associated with insulin sensitivity in a wide range of subjects. |
| Audience | Academic |
| Author | Zaïr, Yassine Laville, Martine Guyomarc'h-Delasalle, Béatrice Krempf, Michel Cariou, Bertrand Chetiveaux, Maud Pouteau, Etienne Disse, Emmanuel |
| AuthorAffiliation | 2 Nestlé Research Center, R&D Santiago, 9260075 Maipú Santiago, Chile 1 INSERM, UMR915; Université de Nantes; CHU Nantes, Clinique d'Endocrinologie, Maladies Métaboliques et Nutrition, l'Institut du Thorax, Nantes, CRNH Nantes, F-44000 France 3 CRNH Rhone-Alpes; INSERM Unit -1060, CarMeN Laboratory and CENS, Lyon1 University; Hospices Civils de Lyon, France Centre Hospitalier Lyon-Sud, F-69310 Pierre Bénite, France |
| AuthorAffiliation_xml | – name: 2 Nestlé Research Center, R&D Santiago, 9260075 Maipú Santiago, Chile – name: 1 INSERM, UMR915; Université de Nantes; CHU Nantes, Clinique d'Endocrinologie, Maladies Métaboliques et Nutrition, l'Institut du Thorax, Nantes, CRNH Nantes, F-44000 France – name: 3 CRNH Rhone-Alpes; INSERM Unit -1060, CarMeN Laboratory and CENS, Lyon1 University; Hospices Civils de Lyon, France Centre Hospitalier Lyon-Sud, F-69310 Pierre Bénite, France |
| Author_xml | – sequence: 1 givenname: Bertrand surname: Cariou fullname: Cariou, Bertrand email: bertrand.cariou@univ-nantes.fr organization: INSERM, UMR915; Université de Nantes; CHU Nantes, Clinique d'Endocrinologie, Maladies Métaboliques et Nutrition – sequence: 2 givenname: Maud surname: Chetiveaux fullname: Chetiveaux, Maud organization: INSERM, UMR915; Université de Nantes; CHU Nantes, Clinique d'Endocrinologie, Maladies Métaboliques et Nutrition – sequence: 3 givenname: Yassine surname: Zaïr fullname: Zaïr, Yassine organization: INSERM, UMR915; Université de Nantes; CHU Nantes, Clinique d'Endocrinologie, Maladies Métaboliques et Nutrition – sequence: 4 givenname: Etienne surname: Pouteau fullname: Pouteau, Etienne organization: Nestlé Research Center, R&D Santiago – sequence: 5 givenname: Emmanuel surname: Disse fullname: Disse, Emmanuel organization: CRNH Rhone-Alpes; INSERM Unit -1060, CarMeN Laboratory and CENS, Lyon1 University; Hospices Civils de Lyon – sequence: 6 givenname: Béatrice surname: Guyomarc'h-Delasalle fullname: Guyomarc'h-Delasalle, Béatrice organization: INSERM, UMR915; Université de Nantes; CHU Nantes, Clinique d'Endocrinologie, Maladies Métaboliques et Nutrition – sequence: 7 givenname: Martine surname: Laville fullname: Laville, Martine organization: CRNH Rhone-Alpes; INSERM Unit -1060, CarMeN Laboratory and CENS, Lyon1 University; Hospices Civils de Lyon – sequence: 8 givenname: Michel surname: Krempf fullname: Krempf, Michel organization: INSERM, UMR915; Université de Nantes; CHU Nantes, Clinique d'Endocrinologie, Maladies Métaboliques et Nutrition |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21736725$$D View this record in MEDLINE/PubMed https://inserm.hal.science/inserm-00611430$$DView record in HAL |
| BookMark | eNp9k91v0zAUxSM0xD7glUcUiQdAIpsdO3byglRNjFWqhMTHs-U6N6kr1x62U9Yn_nXcZSstYsQPSa5_5-T66uQ0O7LOQpa9xOgc45pdYE5JwRGvirqg9ZPsZFc42ns-zk5DWCJECG3Qs-y4xJwwXlYn2a8rGaK2fX5jZFjJXC3Auhbc7UYtnNEql0q3ubRtvv-unFVgo5dROxty6SHXdg0-gNmkTe_ByAht_lPHRdoJg9E2D2CDjnqt4ybVctkOJobn2dNOmgAv7u9n2ferj98ur4vZ50_Ty8msUIyxWMxrzBRWvCm7hilJKaqqmlOMSY2J7Hgj67YrGy45IInJnHJJm67EMO8a1JWMnGXT0bd1ciluvF5JvxFOanFXcL4X0ketDIiSplVhqmqkKCjSYDrHhHUVRqziVZW8PoxeN8N8Be04CXNgerhj9UL0bi0IpqQpUTJ4Pxos_pJdT2YijQv8SiDEcMLRGif8zf33vPsxQIhipYMCY6QFNwRR84ZxVpZ1It_-l8RNugivMEno6xHtZTqztp1LraotLiYlS-fHFG3Hdv4PKq0WVjqlADqd6geCdweCxES4jb0cQhDTr18O2Vf7c9xN4iGdCaAjoLwLwUMnlI53mUtdaCMwEtufQGxzLrY5F7Wg9Z-md7IH50cFF6MgJND24MXSDd6mPD6m-A2gxxT3 |
| CitedBy_id | crossref_primary_10_1016_j_ebiom_2021_103440 crossref_primary_10_1186_s40168_019_0628_3 crossref_primary_10_1016_j_jchromb_2018_02_029 crossref_primary_10_5604_01_3001_0010_5499 crossref_primary_10_1016_j_ijbiomac_2020_10_021 crossref_primary_10_1152_ajpendo_00644_2020 crossref_primary_10_1155_2019_3248527 crossref_primary_10_1016_j_clnu_2012_06_006 crossref_primary_10_5604_01_3001_0010_5496 crossref_primary_10_1016_j_clnu_2019_06_013 crossref_primary_10_2337_dc12_2255 crossref_primary_10_1016_j_fbio_2024_105110 crossref_primary_10_1096_fj_202001692R crossref_primary_10_1210_jc_2013_3367 crossref_primary_10_2337_dc12_2012 crossref_primary_10_1016_j_fshw_2021_04_006 crossref_primary_10_1038_s41387_018_0020_6 crossref_primary_10_1016_j_biochi_2024_11_003 crossref_primary_10_1016_j_clnu_2014_09_018 crossref_primary_10_1177_0004563212473450 crossref_primary_10_1080_10715762_2022_2133705 crossref_primary_10_1136_gutjnl_2017_314307 crossref_primary_10_3390_ijms24032399 crossref_primary_10_1021_acs_jproteome_1c00147 crossref_primary_10_1111_1471_0528_17798 crossref_primary_10_1007_s11695_019_03877_6 crossref_primary_10_1016_j_rbmo_2021_08_005 crossref_primary_10_1002_mnfr_201700703 crossref_primary_10_3390_biom10071049 crossref_primary_10_14341_DM9374 crossref_primary_10_1016_j_bpg_2014_07_004 crossref_primary_10_1111_hepr_13001 crossref_primary_10_1186_s12986_021_00595_8 crossref_primary_10_1152_ajpgi_00152_2020 crossref_primary_10_3390_metabo11050324 crossref_primary_10_1038_s41598_019_51104_0 crossref_primary_10_1016_j_arcmed_2017_11_003 crossref_primary_10_1111_nmo_14758 crossref_primary_10_3390_nu13041104 crossref_primary_10_4239_wjd_v14_i6_632 crossref_primary_10_1016_j_cca_2024_120004 crossref_primary_10_1038_s41392_024_01811_6 crossref_primary_10_3748_wjg_v28_i48_6846 crossref_primary_10_1002_hep_28709 crossref_primary_10_1249_MSS_0000000000003384 crossref_primary_10_1042_CS20230934 crossref_primary_10_1016_j_biochi_2023_04_009 crossref_primary_10_1007_s40618_020_01196_7 crossref_primary_10_1371_journal_pone_0153959 crossref_primary_10_1038_ijo_2015_1 crossref_primary_10_1136_bmjdrc_2021_002287 crossref_primary_10_1016_j_cca_2021_05_036 crossref_primary_10_1093_ijfood_vvae071 crossref_primary_10_1515_cclm_2018_0741 crossref_primary_10_1007_s11892_018_1092_3 crossref_primary_10_1530_EJE_14_0154 crossref_primary_10_1016_j_it_2021_07_005 crossref_primary_10_1111_joim_12599 crossref_primary_10_3389_fcimb_2021_795333 crossref_primary_10_3389_fnins_2015_00199 crossref_primary_10_1038_srep30173 crossref_primary_10_1186_s43556_022_00091_2 crossref_primary_10_1002_ygh2_374 crossref_primary_10_1016_j_exer_2022_109184 crossref_primary_10_1210_clinem_dgab531 crossref_primary_10_1210_clinem_dgab773 crossref_primary_10_1097_MD_0000000000002778 crossref_primary_10_3390_cells10092437 crossref_primary_10_1016_j_jhepr_2021_100301 crossref_primary_10_1080_19490976_2025_2474143 crossref_primary_10_1186_s13020_021_00516_0 crossref_primary_10_1186_s12902_022_01155_8 crossref_primary_10_1016_j_domaniend_2022_106722 crossref_primary_10_3389_fcvm_2020_00022 crossref_primary_10_1097_MOL_0000000000000597 crossref_primary_10_1021_acs_jafc_0c07467 crossref_primary_10_1210_clinem_dgac659 crossref_primary_10_3389_fendo_2022_1034818 crossref_primary_10_1016_j_clnu_2017_06_015 crossref_primary_10_3389_fcimb_2021_634780 crossref_primary_10_1038_srep34070 crossref_primary_10_2147_NSS_S454297 crossref_primary_10_1007_s12072_022_10299_7 crossref_primary_10_1177_0004563218817798 crossref_primary_10_1111_obr_13017 crossref_primary_10_1002_hep4_1490 crossref_primary_10_1016_j_jpba_2020_113617 crossref_primary_10_1177_2010105820952489 crossref_primary_10_1038_s41574_019_0266_7 crossref_primary_10_3389_fendo_2023_1239276 crossref_primary_10_1053_j_gastro_2017_01_055 |
| Cites_doi | 10.1016/j.cmet.2009.08.001 10.1038/nature04330 10.1186/1743-7075-7-73 10.1016/S0092-8674(00)00062-3 10.1074/jbc.M306309200 10.2337/diabetes.31.10.903 10.1073/pnas.0506982103 10.1172/JCI25604 10.1074/jbc.M510258200 10.1016/j.biochi.2004.11.018 10.2337/db11-0030 10.1074/jbc.M209706200 10.1002/hep.23831 10.2165/00003495-200767100-00001 10.1152/physrev.00010.2008 10.1016/S0006-291X(02)02550-0 |
| ContentType | Journal Article |
| Copyright | Cariou et al; licensee BioMed Central Ltd. 2011 COPYRIGHT 2011 BioMed Central Ltd. Distributed under a Creative Commons Attribution 4.0 International License Copyright ©2011 Cariou et al; licensee BioMed Central Ltd. 2011 Cariou et al; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: Cariou et al; licensee BioMed Central Ltd. 2011 – notice: COPYRIGHT 2011 BioMed Central Ltd. – notice: Distributed under a Creative Commons Attribution 4.0 International License – notice: Copyright ©2011 Cariou et al; licensee BioMed Central Ltd. 2011 Cariou et al; licensee BioMed Central Ltd. |
| DBID | C6C AAYXX CITATION NPM ISR 7S9 L.6 7X8 1XC VOOES 5PM DOA |
| DOI | 10.1186/1743-7075-8-48 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed Gale In Context: Science AGRICOLA AGRICOLA - Academic MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef PubMed AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic AGRICOLA PubMed |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology Diet & Clinical Nutrition |
| EISSN | 1743-7075 |
| EndPage | 344 |
| ExternalDocumentID | oai_doaj_org_article_24242514c80c4ec3914b136f51065755 PMC3143920 oai_HAL_inserm_00611430v1 A262511406 21736725 10_1186_1743_7075_8_48 |
| Genre | Journal Article |
| GeographicLocations | France |
| GeographicLocations_xml | – name: France |
| GroupedDBID | --- 04C 0R~ 123 29N 2VQ 2WC 4.4 53G 5VS 7RV 7X7 88E 8FI 8FJ 8G5 A8Z AAFWJ AAHBH AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS AZQEC BAPOH BAWUL BCNDV BENPR BFQNJ BKEYQ BMC BMSDO BPHCQ BVXVI C1A C6C CCPQU CS3 DIK DU5 DWQXO E3Z EAD EAP EAS EBD EBLON EBS EIHBH EJD EMB EMK EMOBN ESTFP ESX F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 H13 HH5 HMCUK HYE IAO ICU IHR IPNFZ ISR ITC KQ8 M1P M2O M48 M~E NAPCQ O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RIG RNS ROL RPM RSV SCM SOJ SV3 TUS UKHRP WOQ WOW XSB AAYXX ALIPV CITATION EX3 NPM PMFND 7S9 L.6 7X8 1XC VOOES 5PM |
| ID | FETCH-LOGICAL-c666t-b816c1c792f96ca44055874113813af79a8df297a7e0a13b47a49f21ebf90f263 |
| IEDL.DBID | M48 |
| ISSN | 1743-7075 |
| IngestDate | Wed Aug 27 01:23:59 EDT 2025 Thu Aug 21 14:14:49 EDT 2025 Fri Sep 12 12:34:45 EDT 2025 Thu Sep 04 21:39:57 EDT 2025 Fri Sep 05 12:44:02 EDT 2025 Tue Jun 17 21:34:26 EDT 2025 Tue Jun 10 20:32:49 EDT 2025 Fri Jun 27 03:41:55 EDT 2025 Mon Jul 21 05:39:10 EDT 2025 Tue Jul 01 02:17:37 EDT 2025 Thu Apr 24 22:50:49 EDT 2025 Sat Sep 06 07:36:44 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | FXR TGR5 type 2 diabetes bile acids hyperinsulinemic-euglycemic clamp energy expenditure insulin resistance |
| Language | English |
| License | Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c666t-b816c1c792f96ca44055874113813af79a8df297a7e0a13b47a49f21ebf90f263 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-8254-1892 0000-0002-4045-0503 0000-0002-1580-8040 0000-0002-6252-9853 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/1743-7075-8-48 |
| PMID | 21736725 |
| PQID | 1999937513 |
| PQPubID | 24069 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_24242514c80c4ec3914b136f51065755 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3143920 hal_primary_oai_HAL_inserm_00611430v1 proquest_miscellaneous_879676228 proquest_miscellaneous_1999937513 gale_infotracmisc_A262511406 gale_infotracacademiconefile_A262511406 gale_incontextgauss_ISR_A262511406 pubmed_primary_21736725 crossref_citationtrail_10_1186_1743_7075_8_48 crossref_primary_10_1186_1743_7075_8_48 springer_journals_10_1186_1743_7075_8_48 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011-07-07 |
| PublicationDateYYYYMMDD | 2011-07-07 |
| PublicationDate_xml | – month: 07 year: 2011 text: 2011-07-07 day: 07 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Nutrition & metabolism |
| PublicationTitleAbbrev | Nutr Metab (Lond) |
| PublicationTitleAlternate | Nutr Metab (Lond) |
| PublicationYear | 2011 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | 10.1186/1743-7075-8-48-B11 10.1186/1743-7075-8-48-B12 10.1186/1743-7075-8-48-B20 10.1186/1743-7075-8-48-B10 - 10.1186/1743-7075-8-48-B5 10.1186/1743-7075-8-48-B3 10.1186/1743-7075-8-48-B2 10.1186/1743-7075-8-48-B1 10.1186/1743-7075-8-48-B13 10.1186/1743-7075-8-48-B9 10.1186/1743-7075-8-48-B19 10.1186/1743-7075-8-48-B8 10.1186/1743-7075-8-48-B7 10.1186/1743-7075-8-48-B6 10.1186/1743-7075-8-48-B18 12524422 - J Biol Chem. 2003 Mar 14;278(11):9435-40 12419312 - Biochem Biophys Res Commun. 2002 Nov 15;298(5):714-9 16400329 - Nature. 2006 Jan 26;439(7075):484-9 11030617 - Cell. 2000 Sep 15;102(6):731-44 19126757 - Physiol Rev. 2009 Jan;89(1):147-91 20815878 - Nutr Metab (Lond). 2010 Sep 03;7:73 15733743 - Biochimie. 2005 Jan;87(1):93-8 6759223 - Diabetes. 1982 Oct;31(10):903-10 382871 - Am J Physiol. 1979 Sep;237(3):E214-23 12917447 - J Biol Chem. 2003 Oct 24;278(43):41930-7 16446356 - J Biol Chem. 2006 Apr 21;281(16):11039-49 18682704 - Mol Syst Biol. 2008;4:214 21593203 - Diabetes. 2011 Jul;60(7):1861-71 16410358 - Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1006-11 17412431 - Trends Pharmacol Sci. 2007 May;28(5):236-43 19723493 - Cell Metab. 2009 Sep;10(3):167-77 17600387 - Drugs. 2007;67(10):1383-92 20725912 - Hepatology. 2010 Oct;52(4):1455-64 16557297 - J Clin Invest. 2006 Apr;116(4):1102-9 2614267 - J Lipid Res. 1989 Oct;30(10):1647-52 870827 - N Engl J Med. 1977 Jun 16;296(24):1365-71 |
| References_xml | – ident: 10.1186/1743-7075-8-48-B13 doi: 10.1016/j.cmet.2009.08.001 – ident: 10.1186/1743-7075-8-48-B10 doi: 10.1038/nature04330 – ident: - doi: 10.1186/1743-7075-7-73 – ident: 10.1186/1743-7075-8-48-B2 doi: 10.1016/S0092-8674(00)00062-3 – ident: 10.1186/1743-7075-8-48-B3 doi: 10.1074/jbc.M306309200 – ident: 10.1186/1743-7075-8-48-B18 doi: 10.2337/diabetes.31.10.903 – ident: 10.1186/1743-7075-8-48-B8 doi: 10.1073/pnas.0506982103 – ident: 10.1186/1743-7075-8-48-B7 doi: 10.1172/JCI25604 – ident: 10.1186/1743-7075-8-48-B6 doi: 10.1074/jbc.M510258200 – ident: 10.1186/1743-7075-8-48-B5 doi: 10.1016/j.biochi.2004.11.018 – ident: 10.1186/1743-7075-8-48-B9 doi: 10.2337/db11-0030 – ident: 10.1186/1743-7075-8-48-B12 doi: 10.1074/jbc.M209706200 – ident: 10.1186/1743-7075-8-48-B19 doi: 10.1002/hep.23831 – ident: 10.1186/1743-7075-8-48-B20 doi: 10.2165/00003495-200767100-00001 – ident: 10.1186/1743-7075-8-48-B1 doi: 10.1152/physrev.00010.2008 – ident: 10.1186/1743-7075-8-48-B11 doi: 10.1016/S0006-291X(02)02550-0 – reference: 870827 - N Engl J Med. 1977 Jun 16;296(24):1365-71 – reference: 6759223 - Diabetes. 1982 Oct;31(10):903-10 – reference: 12419312 - Biochem Biophys Res Commun. 2002 Nov 15;298(5):714-9 – reference: 20815878 - Nutr Metab (Lond). 2010 Sep 03;7:73 – reference: 12524422 - J Biol Chem. 2003 Mar 14;278(11):9435-40 – reference: 16446356 - J Biol Chem. 2006 Apr 21;281(16):11039-49 – reference: 19723493 - Cell Metab. 2009 Sep;10(3):167-77 – reference: 11030617 - Cell. 2000 Sep 15;102(6):731-44 – reference: 12917447 - J Biol Chem. 2003 Oct 24;278(43):41930-7 – reference: 16557297 - J Clin Invest. 2006 Apr;116(4):1102-9 – reference: 15733743 - Biochimie. 2005 Jan;87(1):93-8 – reference: 16410358 - Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1006-11 – reference: 20725912 - Hepatology. 2010 Oct;52(4):1455-64 – reference: 17600387 - Drugs. 2007;67(10):1383-92 – reference: 16400329 - Nature. 2006 Jan 26;439(7075):484-9 – reference: 2614267 - J Lipid Res. 1989 Oct;30(10):1647-52 – reference: 19126757 - Physiol Rev. 2009 Jan;89(1):147-91 – reference: 21593203 - Diabetes. 2011 Jul;60(7):1861-71 – reference: 17412431 - Trends Pharmacol Sci. 2007 May;28(5):236-43 – reference: 18682704 - Mol Syst Biol. 2008;4:214 – reference: 382871 - Am J Physiol. 1979 Sep;237(3):E214-23 |
| SSID | ssj0033490 |
| Score | 2.2887015 |
| Snippet | Background
Accumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA treatment has been shown to improve glucose... Accumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA treatment has been shown to improve glucose tolerance and... Background Accumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA treatment has been shown to improve glucose... BACKGROUND: Accumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA treatment has been shown to improve glucose... Abstract Background Accumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA treatment has been shown to improve... |
| SourceID | doaj pubmedcentral hal proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 48 |
| SubjectTerms | adults Bile acids blood glucose blood lipids Blood sugar body mass index Brief Communication calorimetry Chenodeoxycholic acid Cholic acid Clinical Nutrition deoxycholic acid energy expenditure Food and Nutrition FXR gas chromatography gender glucose glucose tolerance homeostasis Human health and pathology humans hyperinsulinemic-euglycemic clamp insulin insulin resistance Life Sciences lipid content lipids mass spectrometry Medicine Medicine & Public Health Metabolic Diseases mice multivariate analysis noninsulin-dependent diabetes mellitus patients Physiological aspects TGR5 Tissues and Organs type 2 diabetes volunteers |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals (DOAJ) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LbxMxELagJy4IWh4LBRnE67Lq7trx2sfwiAKCHoBKvVlex6aREqfKJlV74q8z43WiLlXEhWO8o43XM7a_sWe-IeSVZz6WDckBK0twUBqRG4sJPgzAvHHK17F827djMT7hX04Hp9dKfWFMWEcP3A3cEaYvwB7MrSwsd5apkjclEx5sCe8MIntpoYqNM9WtwYxxlVIhWV7DrpjoGkspjrZtOZ6k9bajyNq_XZtvn2Fo5E3ceTN88q871Lg1je6RuwlT0mH3LffJLRf2ycEwgD89v6JvaIzyjMfn-yT7OHUraEt8oDN6vKHjPyC_R6bFKGh6DpB6bijoMywmbnEZ18ippcZOJ9SECb3-22LiY0jsuy01S0enAYM93OwKHi5jtoybUDzxpSn0nbYYN98VroA2GllA2gfkZPTp54dxngo05Ba8nlXeyFLY0taq8kpYwwH8DSRAlBJgADO-VkZOfKVqU7vClKzhteHKV6VrvCp8JdhDshcWwT0mVBQeXuDRRS65d40Uzls2UE4NnGpqnpF8oydtE3s5FtGY6ejFSKFRrxr1qqXmMiNvt_LnHW_HTsn3qPatFPJtxwawQp2sUP_LCjPyEo1GI6NGwJCdX2bdtvrzj-96WAl04wA4QZ-SkF9A361JGRAwAkjC1ZM87EnClLe9x6_BNns9Hg-_gjSsWnONqBRQcHFRZuTFxno1vgLj6YJbrFuN5BMATGGWZoTukJG1ErBVVjBCjzqD3_4j-LFM1BV8dt2bCr0u9Z-E6VkkL2fQNVUVGXm3mTQ6rZrtDgU9-R8KekrudLcBeDB_SPZWy7V7BnBy1TyPK8cfnHRrfg priority: 102 providerName: Directory of Open Access Journals – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfYkBAvCDo-AgMZxNdLtCR2HfuxFKqC2B6ASXuzHMdmldp0alrEnvjXuXPdaqGqxGOdq-vmzuff2Xc_E_LaMx-uDUkBK0sIUCqRGosFPgzAvHHKl-H6ttMzMT7nXy76FzFBFmthbp7f51KcIGBOS1jXUtz3OiC3oeMMLXkohhuPyxhXWSRk3P1OZ8EJvPxb73twicmPu8hyN0Hyn1PSsPiM7pN7ETXSwVrND8gt1_TI0aCBiHl2Td_SkMcZNsh7JPk4cUtoi4yfU3q2IdzvkTun8Sj9iPwZmRZTnukV4OeZoaC8Zl67-e_gECeWGjupqWlqevOzxSrHJlLtttQsHJ00mNnhptfwcBFKY1xNcXuXxjx32mKS_PqWCmijgfKjfUjOR59-DMdpvI0htRDiLNNK5sLmtlSFV8IaDkivLwGP5LDmM-NLZWTtC1Wa0mUmZxUvDVe-yF3lVeYLwR6Rw2beuCeEisxDBx7j4Zx7V0nhvGV95VTfqarkCUk3KtM2UpXjjRlTHUIWKTSqWKOKtdRcJuTdVv5qTdKxV_IDWsBWCsm1QwPYnI5zVWPFDMA-bmVmubNM5bzKmfDgvvCYqp-QV2g_GukzGszP-WlWbas_f_-mB4XAmA1QEowpCvk5jN2aWO4AbwAZtzqSxx1JmN-28_gNmGlnxOPBV5AGFzXTCEEB8ma_8oS83Biyxi4wea5x81WrkWkCUCjMnITQPTKyVALWxQLe0OO17W9_EYJWJsoC_nbZmRWdIXWfNJPLwFTOYGiqyBLyfjN_dHSR7R4FPf1_0Wfk7nqDH_faj8nhcrFyzwEhLqsXwT38BdJWXXI priority: 102 providerName: Springer Nature |
| Title | Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults |
| URI | https://link.springer.com/article/10.1186/1743-7075-8-48 https://www.ncbi.nlm.nih.gov/pubmed/21736725 https://www.proquest.com/docview/1999937513 https://www.proquest.com/docview/879676228 https://inserm.hal.science/inserm-00611430 https://pubmed.ncbi.nlm.nih.gov/PMC3143920 https://doaj.org/article/24242514c80c4ec3914b136f51065755 |
| Volume | 8 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3djxIxEG_k7sUXo3d-rJ6kGr9eVtkP2u2DMRweQaLE3EnCW9Mt7R0J7J4smOPJf92Z7oKuSOIToR12S9uZ_qad-ZWQFzay7toQH7ByAg5KynylMcEnAjCvjLDcXd_2Zcj6o3gwbo9_xz9VHVj807XD-6RGi9nbm-_rD6Dw753CJ-wdgmqfw9rn495Ygxy6syIM44u3JwpRFIsqObKUrQgcd39fW6Acj__WWjeuMFhyF4nuBlT-darqFqveXXKnQpm0U06Le-SWyY7IcScDD3u-pq-oi_t0G-pHxPs4NUsoqxhCZ3S4Ieg_Jj97qsC4aHoNIHuuKIxwlk9MfuOs5lRTpacTqrIJ_fO7xlTIrOLjLahaGDrNMPzDzNZQuXD5M2ZCcQ-YVsHwtMBI-vIqCyijjhekuE9GvbNv3b5fXdnga_CDln6aBEwHmovQCqZVDHCwnQBoCQAYRMpyoZKJDQVX3LRUEKUxV7GwYWBSK1o2ZNEDcpDlmXlEKGtZeIBFpzmIrUkTZqyO2sKIthEpjz3ib8ZJ6orPHK_VmEnn1yRM4rhKHFeZyDjxyOut_HXJ5LFX8hSHfSuFDNyuIF9cykqhJabVADaMddLSsdGRCOI0iJgFG4dnWW2PPMdJI5FjI8Mgnku1Kgr56eJcdkKGjh1AKWhTJWRzaLtWVU4E9ADSctUkT2qSYAR0rfolzM1ai_udzyANdmwuEacCLm79CDzybDN7JT4CI-wyk68KiXQUAFVBbz1C98gkXDBYPEPooYflhN--ETzbiPEQ_javqUKtSfWabHrl6MwjaJoIWx55s1EauTEDewbo8f_07RNyu9z_x634E3KwXKzMUwCQy7RJGnzMm-Sw0xlcDODz9Gz49RxKu6zbdJsyTWc7fgEpCW8_ |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfYkIAXBB0fgQEG8bGXiCRO7fixFKoO2j7AJu3NclybVWrTqWkRe-Jf5851q4WqEo-1r6mbO59_Z9_9TMhbx5y_NiQGrFxAgFLyWBss8GEA5rWVTvjr24Yj3j_Pv160L0KCLNbC3Dy_Twv-EQFzLGBdi3Hf64DcxlNL5Mjv8u7G4zKWyyQQMu5-p7HgeF7-rfc9uMTkx11kuZsg-c8pqV98eg_I_YAaaWet5ofklq1a5KhTQcQ8u6bvqc_j9BvkLRJ9ntgltAXGzykdbQj3W-TOMBylH5E_PV1jyjO9Avw80xSUV83Hdv7bO8SJodpMxlRXY3rzs8EqxypQ7dZULyydVJjZYafX0LnwpTF2THF7l4Y8d1pjkvz6lgpoo57yo35Ezntfzrr9ONzGEBsIcZZxWaTcpEbIzEludA5Ir10AHklhzWfaCamLscuk0MImOmVlLnQuXZba0snEZZw9JofVvLJPCeWJgwc4jIfT3Nmy4NYZ1pZWtq0sRR6ReKMyZQJVOd6YMVU-ZCm4QhUrVLEqVF5E5MNW_mpN0rFX8hNawFYKybV9A9icCnNVYcUMwL7cFInJrWEyzcuUcQfuC4-p2hF5g_ajkD6jwvycn3pV1-r0x3fVyTjGbICSYExByM1h7EaHcgd4A8i41ZA8bkjC_DaN7ndgpo0R9zsDkAYXNVMIQQHyJr_SiLzeGLLCR2DyXGXnq1oh0wSgUJiSEaF7ZAohOayLGbyhJ2vb3_4iBK2Miwz-tmjMisaQmj3V5NIzlTMYmsySiJxs5o8KLrLeo6Bn_y_6itztnw0HanA6-vac3Ftv9uO--zE5XC5W9gWgxWX50ruKv2s3YGE |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELf2IU28IOiABQYYxNdLtHzViSVeCqPqylYhxqS9WY5jb5XatGpaxJ7417lznIpQVeKx9jV1c77z7-y7nwl5Y2Jjrw3xAStnEKDkzJcKC3xiAPNSc5Pa69suRmxwlQyvu9c75GNTC2Oz3ZsjybqmAVmayuXJvDC1iWfsBGG0n8Jq5-Nu2C7Zz7qcQ-i13-sNL4eNJ47jhAeOqHHzW62FyPL1r73y7i0mRW4izs3EyX9OT-2i1H9A7js0SXu1-h-SHV12yGGvhEh6ekffUZvfaTfOO8Q7HesltDkm0AkdNUT8HXJw4Y7YD8nvvqwwFZrOAVdPJQWllrNCz35ZRzlWVKpxQWVZ0L8_K6x-LB0Fb0XlQtNxiRkfenIHnQtbMqMLitu-1OW_0wqT5-vbK6CNWiqQ6hG56n_58Xngu1safAWhz9LPs5CpUKU8MpwpmQAC7GaAU0LAArE0KZdZYSKeylQHMozzJJUJN1Goc8MDE7H4MdkrZ6U-IpQFBh5gME4OE6PzjGmj4i7XvKt5niYe8RuVCeUozPEmjYmwoUzGBKpYoIpFJpLMI-_X8vOavGOr5CecAWspJN22DbPFjXA2LLCSBuBgorJAJVrFPEzyMGYG3BoeX3U98hrnj0BajRLzdm7kqqrE2eV30YsYxnKAnmBMTsjMYOxKujIIeAPIxNWSPG5Jgt2rVvdbmKatEQ965yANrmsqEJoCFA5-hh551UxkgY_ApLpSz1aVQAYKQKdgqh6hW2SylDNYLyN4Q0_qub_-RQhmY5ZG8LfTllW0htTuKce3lsE8hqHxKPDIh8Z-hHOd1RYFPf1_0Zfk4NtpX5yfjb4-I_fqMwDcjj8me8vFSj8HELnMXzhf8Qd8Lmof |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fasting+plasma+chenodeoxycholic+acid+and+cholic+acid+concentrations+are+inversely+correlated+with+insulin+sensitivity+in+adults&rft.jtitle=Nutrition+%26+metabolism&rft.au=Cariou%2C+Bertrand&rft.au=Chetiveaux%2C+Maud&rft.au=Za%C3%AFr%2C+Yassine&rft.au=Pouteau%2C+Etienne&rft.date=2011-07-07&rft.pub=BioMed+Central+Ltd&rft.issn=1743-7075&rft.eissn=1743-7075&rft.volume=8&rft.spage=48&rft_id=info:doi/10.1186%2F1743-7075-8-48&rft.externalDBID=ISR&rft.externalDocID=A262511406 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1743-7075&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1743-7075&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1743-7075&client=summon |